Cargando…

Birth of two healthy girls following preimplantation genetic diagnosis and gestational surrogacy in a rapidly progressive autosomal dominant polycystic kidney disease case using tolvaptan

Detalles Bibliográficos
Autores principales:	Peces, Ramón, Mena, Rocío, Peces, Carlos, Cuesta, Emilio, Lapunzina, Pablo, Selgas, Rafael, Nevado, Julián
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323138/ https://www.ncbi.nlm.nih.gov/pubmed/34345424 http://dx.doi.org/10.1093/ckj/sfab082

Ejemplares similares

Co‐occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2
por: Peces, Ramón, et al.
Publicado: (2020)

Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease
por: Peces, Ramón, et al.
Publicado: (2009)

Nephrotic Syndrome and Idiopathic Membranous Nephropathy Associated with Autosomal-Dominant Polycystic Kidney Disease
por: Peces, Ramón, et al.
Publicado: (2011)

Bilineal inheritance of type 1 autosomal dominant polycystic kidney disease (ADPKD) and recurrent fetal loss
por: Peces, Ramón, et al.
Publicado: (2008)

Sacral radicular cysts in autosomal dominant polycystic kidney disease
por: Peces, Ramón, et al.
Publicado: (2009)

Severe congenital nephrogenic diabetes insipidus in a compound heterozygote with a new large deletion of the AQP2 gene. A case report
por: Peces, Ramón, et al.
Publicado: (2019)

Historical and geographical distribution of the founder mutation c.610G>A; p.Ala204Thr in the CLCNKB gene linked to Bartter syndrome type III in Spain
por: Peces, Ramón, et al.
Publicado: (2021)

Rapidly Progressing to ESRD in an Individual with Coexisting ADPKD and Masked Klinefelter and Gitelman Syndromes
por: Peces, Ramón, et al.
Publicado: (2022)

Giant Bilateral Renal Angiomyolipomas and Lymphangioleiomyomatosis Presenting after Two Successive Pregnancies Successfully Treated with Surgery and Rapamycin
por: Peces, Ramón, et al.
Publicado: (2011)

A Spanish Family with Gordon Syndrome Due to a Variant in the Acidic Motif of WNK1
por: Peces, Ramón, et al.
Publicado: (2023)

Living kidney transplantation between brothers with unrecognized renal amyloidosis as the first manifestation of familial Mediterranean fever: a case report
por: Peces, Ramón, et al.
Publicado: (2017)

Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
por: Gilbert, Rodney D., et al.
Publicado: (2017)

Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
por: Bellos, Ioannis
Publicado: (2021)

Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease
por: Magistroni, Riccardo
Publicado: (2018)

Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
por: Kim, Ha Yeon, et al.
Publicado: (2018)

Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
por: Anderegg, Manuel A., et al.
Publicado: (2020)

Risks in Surrogacy Considering the Embryo: From the Preimplantation to the Gestational and Neonatal Period
por: Simopoulou, M., et al.
Publicado: (2018)

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
por: Sans-Atxer, Laia, et al.
Publicado: (2018)

Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
por: Müller, Roman-Ulrich, et al.
Publicado: (2018)

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
por: Kunizawa, Kyohei, et al.
Publicado: (2018)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
por: Iijima, Hiroko, et al.
Publicado: (2022)

Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2023)

Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
por: Kim, Yaerim, et al.
Publicado: (2023)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017)

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
por: Lanke, Shankar, et al.
Publicado: (2019)

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients
por: Nakatani, Shinya, et al.
Publicado: (2020)

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022)

Safety and Tolerability of Tolvaptan in an Autosomal Dominant Polycystic Kidney Disease Spanish Cohort: A Real-World Experience
por: Guerra-Torres, Xavier E, et al.
Publicado: (2020)

Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations
por: Moriyama, Tomofumi, et al.
Publicado: (2020)

Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease
por: Naranjo, Javier, et al.
Publicado: (2022)

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
por: Lioudis, Michael, et al.
Publicado: (2023)

Feasibility of artificial intelligence-based decision supporting system in tolvaptan prescription for autosomal dominant polycystic kidney disease
por: Shin, Jung Hyun, et al.
Publicado: (2023)

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial
por: Muto, Satoru, et al.
Publicado: (2017)

Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
por: Agraz-Pamplona, I., et al.
Publicado: (2020)

The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
por: Uchiyama, Kiyotaka, et al.
Publicado: (2021)

Tolvaptan ameliorated kidney function for one elderly autosomal dominant polycystic kidney disease patient: A case report
por: Zhou, Li, et al.
Publicado: (2022)

Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis
por: Lu, Jingkui, et al.
Publicado: (2022)

Combined Preimplantation Genetic Testing for Autosomal Dominant Polycystic Kidney Disease: Consequences for Embryos Available for Transfer
por: Mir Pardo, Pere, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_051ukbu0j48pgnoei19q3baq01